We are live on
!
Find out more
Pacira BioSciences
PCRX
PCRX
180 hedge funds and large institutions have $2.29B invested in Pacira BioSciences in 2016 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 77 increasing their positions, 60 reducing their positions, and 56 closing their positions.
New
Increased
Maintained
Reduced
Closed
28% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 60
16% less funds holding
Funds holding: 214 → 180 (-34)
16% less call options, than puts
Call options by funds: $22.9M | Put options by funds: $27.3M
30% less capital invested
Capital invested by funds: $3.29B → $2.29B (-$999M)
45% less funds holding in top 10
Funds holding in top 10: 11 → 6 (-5)
57% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 56
Holders
180
Holders Change
-34
Holders Change %
-15.89%
% of All Funds
4.8%
Holding in Top 10
6
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-45.45%
% of All Funds
0.16%
New
24
Increased
77
Reduced
60
Closed
56
Calls
$22.9M
Puts
$27.3M
Net Calls
-$4.42M
Net Calls Change
+$14.1M
Top Buyers
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$94.2M |
| 2 |
FAM
Fred Alger Management
New York
|
+$63.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.8M |
| 4 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
+$15.9M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$15.9M |
